Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company’s ongoing Phase I/II clinical trials of the Company’s investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-11
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1803777103-b9626d35c9fd4424ae7ecc3b6d58a558.jpg "Accountant Career Path and Qualifications")
:max_bytes(150000):strip_icc():format(jpeg)/AFFLUENT.MILLENNIAL.HERO.GettyImages-868506558_2600-84706e45802340b1865d4b49c285a662.jpg "The Affluent Millennial Investing Survey")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2151279555-f38549a64433496982ff93944b309afb.jpg "5 Transamerica Mutual Funds to Consider")
